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Chemotherapeutic Efficacy in Small Cell Lung Cancer
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Bhupendra Rawal, MS,‡ Michael J. Schell, PhD,‡ Brian P. Mullaney, MD, PhD,§
and Gerold Bepler, MD, PhD*†
Introduction: One-size-fits-all chemotherapy does not improve sur-
vival in patients with small cell lung cancer (SCLC). Excision repair
cross-complementing group 1 (ERCC1), ribonucleotide reductase 1
(RRM1), thymidylate synthase (TS), and topoisomerase 2 (Topo2)
expression levels are predictive of chemotherapeutic efficacy in some
malignancies. Our aim was to determine the expression levels of
these proteins to assess their potential clinical utility in SCLC.
Methods: We used an immunofluorescence-based automated quan-
titative technique to score RRM1, ERCC1, TS, and Topo2 levels in
tumor specimens from 100 patients with SCLC and immunohisto-
chemistry to semiquantitatively score levels of TS, 5-phosphoribo-
syl-glycinamide formyl-transferase, and folyl-polyglutamate syn-
thase expression. Confocal microscopy was used for subcellular
localization in SCLC cells.
Results: RRM1, ERCC1, and Topo2 staining was predominantly
nuclear and TS mainly cytoplasmic. Using immunohistochemistry,
we found that TS (antibody 106) and TS (antibody 4H4) scores were
strongly correlated (r  0.82, p  0.0001). By automated quanti-
tative technique, RRM1 and Topo2 levels were highly correlated
(r 0.56, p 0.0001). ERCC1 and TS levels had a narrow and low
range of expression. There was no correlation between any of these
biomarkers and patients’ age or sex.
Conclusion: Considering this clinical evidence, expression levels of
RRM1 and Topo2 may have utility for chemotherapy customiza-
tion. Clinical validation of their predictive power is desirable in a
prospective clinical trial.
Key Words: Predictive biomarkers, Chemosensitivity, Small cell
lung cancer (SCLC), Immunofluorescence-based automated quanti-
tative analysis (AQUA).
(J Thorac Oncol. 2010;5: 484–490)
Small cell lung cancer (SCLC) accounts for approximately15% of all new lung cancer cases in the United States.1
SCLC is characterized by early dissemination, and 70 to 80%
of patients have widely metastatic disease at diagnosis (ex-
tensive stage, ES-SCLC). SCLC is considered a chemother-
apy-responsive disease, and etoposide-platinum is the stan-
dard, first-line treatment in the United States. However,
despite initial response rates of more than or equal to 60%
and complete response rates of 20–30%, the median survival
time and 2-year survival rate range from 7 to 10 months and
10 to 20%, respectively. No significant improvements in the
efficacy of systemic chemotherapy have been achieved in the
past 30 years.2,3
Newer cytotoxic drugs have been tested in patients with
SCLC.4 Taxanes (paclitaxel5 and docetaxel6), topoisomerase
inhibitors (topotecan7 and irinotecan8), and antimetabolites
(pemetrexed9 and gemcitabine10) have demonstrated accept-
able activity as single agents and in combination with plati-
num agents. Unfortunately, in phase III trials, they have
failed to produce a survival advantage.11–14 Novel approaches
that focus on specific genomic characteristics of individual
tumors may provide tools to overcome this stalemate.
Pharmacogenomics centers on the principle that molec-
ular characteristics observed in tumors have the potential to
affect therapeutic decisions and to improve patient outcomes.
Specifically, pharmacogenomics has the potential to allow
clinicians to select chemotherapy drugs that will give patients
maximal benefit while simultaneously minimizing toxicity.15,16
Specific gene products that may lend themselves to such an
approach in SCLC include (1) RRM1, the regulatory subunit
of ribonucleotide reductase, the enzyme responsible for the
supply of deoxyribonucleotides for DNA synthesis, and the
target of gemcitabine17; (2) topoisomerase 2 (Topo2; subunits
 and ), an enzyme that regulates the topological state of
DNA, facilitating replication, mitosis, and chromatin conden-
sation,18 and the target of etoposide; (3) excision repair cross
complementing group 1 (ERCC1), a component of the 5
endonuclease of the nucleotide excision repair complex,
which is responsible for cisplatin-induced DNA damage re-
pair19; and (4) thymidylate synthase (TS), an enzyme respon-
sible for thymidine production for DNA synthesis and one of
the targets of pemetrexed.20
Although not yet shown in SCLC, in different tumor
types and using different methodologies, evidence from mul-
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tiple preclinical and clinical studies has been accumulating to
support the role of these proteins as predictive biomarkers of
activity for their respective cytotoxic agents.21–32 Further-
more, their potential therapeutic advantage is highlighted by
current prospective phase II33 and III34 clinical trials in
non-SCLC (NSCLC), where these biomarkers have been
used to select cytotoxic agents with promising clinical out-
comes data.
In this study, our aim was to describe the pattern and
range of expression levels as well as to find correlations in the
expression levels among these biomarkers in a large cohort of
patients with SCLC. Two biomarkers in particular, Topo2
and RRM1, showed promising patterns of expression that can
be used to initiate a prospective clinical trial with individu-
alized treatment combinations for patients with SCLC.
METHODS
Tissue Microarray Construction
A custom tissue microarray (TMA) was provided by Eli
Lilly & Co. (Indianapolis, IN). The array (OD-CT-RsLug01)
encompasses triplicate samples from 100 patients with
SCLC. It was constructed by Shanghai Biochip (Shanghai,
China), using 1.0-mm tissue cores from formalin-fixed and
paraffin-embedded (FFPE) tissue blocks of patients with
confirmed SCLC. Sections of 5 m thickness were cut,
transferred to 4 adhesive-coated slides using tape (Instru-
medics, St. Louis, MO), and briefly exposed to ultraviolet
light to enhance adherence. The surface of the TMA speci-
mens was protected from light and environment by an opaque
air-tight film. Clinical outcomes data are not available from
patients who contributed specimens to this array (except age
and gender). Investigational Review Board approval was
obtained before performing the molecular analyses.
In Situ Detection and Quantification of Protein
Expression
Immunofluorescence combined with automated quanti-
tative analysis (AQUA) was used to assess in situ expression
of the target molecules.35 Antigens were retrieved by incu-
bating the tissue in a microwave oven for 15 minutes in 0.01
mol/L sodium citrate, Tris-HCl, or Tris-EDTA buffer at an
optimized pH.36 The slides were blocked for 30 minutes with
0.3% bovine serum albumin and then incubated overnight at
4°C in optimal concentrations of antisera or antibodies to
detect RRM1, ERCC1, TS, and Topo2. The RRM1 anti-
serum was custom made in rabbits, affinity purified, and
designated R1AS-6b.37 Commercial antibodies were used for
the analysis of ERCC1 (clone SPM-243; Santa Cruz Biotech-
nology Inc., Santa Cruz, CA), TS (clone 106; Abcam, Cam-
bridge, MA), and Topo2 (clone Ki-S1; Dako Cytomation,
Carpinteria, CA). For identification of carcinomatous cells,
antibodies to cytokeratin were used (murine antihuman pan-
cytokeratin AE1/AE3, 1:200, #M3515, Dako Cytomation;
rabbit antihuman pancytokeratin AE1/AE3, 1:200, #Z0622,
Dako Cytomation, Carpinteria, CA). Slides were washed and
incubated with two different secondary antibodies for 1 hour:
Envision-labeled polymer horseradish peroxidase anti-rabbit
(#K4011) or Envision-labeled polymer horseradish peroxi-
dase anti-mouse (#K4007), specific to the primary antibody
used for target protein detection (1:200; Alexa 555 goat
anti-mouse [A21424] or goat anti-rabbit [A21429]), is based
on the source of the anticytokeratin antibody (1:200) (Dako,
Carpinteria, CA). For fluorescence amplification, slides were
exposed to Cy5-tyramide (1:50) for 10 minutes at room
temperature. Slides were mounted with Prolong Gold anti-
fade reagent with 4-6-diamidino-2-phenylindole (DAPI) so-
lution. The final TMA slides were scanned with SpotGrabber,
and image data were analyzed with AQUA (PM-2000, soft-
ware version 1.6; HistoRx, New Haven, CT). For software
version 1.6, the maximal range of scores is 0 to 33,333.
Immunohistochemistry (IHC) assays were developed,
validated, and performed at a centralized laboratory (Ventana
Medical Systems, Tucson, AZ) by Benchmark XT automated
immunostainer. Commercial antibodies for TS were used
(monoclonal TS106, Abcam, #AB3145 primary dilution
1:10; monoclonal 4H4B1, Zymed, #18-0399, primary dilu-
tion 1:20) with 1-hour primary incubation with CC1 standard
(Ventana, #950-124) at room temperature and ultraView
detection kit (Ventana, #760-500) for TS 4H4B1 or iView-
PolymerDAB detection system (Ventana, #760-115) for
TS106. Murine monoclonal antibodies for folyl-polygluta-
mate synthase (FPGS) and 5-phosphoribosyl-glycinamide
formyl-transferase (GARFT) were developed by Integrated
Biology/Translational Medicine at Eli Lilly (both primary
dilution 1:160, with Ultraview detection). Anti-FPGS mAb
was raised against purified recombinant N-terminal His-
tagged full-length human FPGS protein. The mAb binds the
full-length antigen with a dissociation constant of 2.58 
1012 M and stains a single protein at approximately 61 kDa
in Western blots of whole cell extracts.38 Anti-GARFT mAb
was raised against recombinant N-terminal His-tagged full-
length human GARFT protein. The mAb binds the full-length
antigen with a dissociation constant of 1.14  1010 M and
stains a single protein at approximately 110 kDa in Western
blots of whole cell extracts.39 Expression was assessed semi-
quantitatively using the hybrid-score (H score) method. For
this, the percentage of tumor cells stained for a marker for
each intensity category on a scale of 0 to 3 (for absent, slight,
moderate, and marked staining, respectively) was enumer-
ated. The percentage of cells in each category was then
multiplied by its value, and the products were added. The
maximal range of H scores was 0 to 300.40
Confocal Microscopy
Four different SCLC cell lines (H69, H82, H209, and
H211) were grown in 75 cm2 flasks. Cells (5  104) were
placed in a tube containing 250 L of 20% fetal bovine serum
phosphate-buffered saline (PBS). Cell suspensions (250 L)
were added to each cytofunnel slot and spun at 570 rpm for
5 minutes. The cytofunnels were carefully removed from the
slides. After the wet slides were air dried, the cells were fixed
by incubation for 20 minutes in 4% paraformaldehyde in PBS
and washed in PBS. They were permeabilized for 1 hour in
0.25% Triton X-100-PBS and washed in PBS. RRM1,
ERCC1, TS, and Topo2 (1:100) antibodies were diluted in
binding buffer (1% bovine serum albumin, 0.1% Nonidet
P40, PBS), added directly onto the cell spots (a Parafilm
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square covered the spots to prevent the cells from drying out),
and incubated for 1 hour. After slides were washed in PBS,
they were incubated for 45 minutes with 1:500 dilutions of
Alexa Fluor 555 anti-mouse IgG (Molecular Probes-Invitro-
gen, Eugene, OR). The slides were washed with PBS and
covered using ProLong Gold antifade reagent with DAPI
(Molecular Probes-Invitrogen). As negative controls, the
same procedure was performed without primary antibody.
Samples were viewed with an inverted Zeiss LSM 510
confocal microscope with a 363/1.20NA water-immersion
objective (Carl Zeiss, Oberkochen, Germany). Nuclei were
observed with DAPI. Images were produced with dual pho-
tomultiplier detectors and the LSM 5 version 3.2.0.115 soft-
ware suite.
Statistical Analysis/Methods
The primary objective was to describe the AQUA score
and H-score expression distribution for each of the biomar-
kers. Descriptive statistics (mean, standard deviation, median,
minimum, and maximum values) were calculated using the
average values for the AQUA scores and H scores from
triplicate readings for each gene and treated as independent
continuous variables. TS AQUA scores in the first three rows
(13 values) of the TMA were excluded from analysis because
the placement of the tissues on the slide precluded an accurate
reading with the AQUA technology.
The secondary objective was to assess the correlations
among the expression levels of the target proteins in their
major cellular compartments, i.e. RRM1 nuclear versus
ERCC1 nuclear, RRM1 nuclear versus Topo2 nuclear,
RRM1 nuclear versus TS cytoplasmic, and so forth. Age and
gender (the only clinical data available) were also correlated
with protein expression. Spearman (rank) correlation was
used to assess the associations between the different proteins
and between proteins and age. Wilcoxon rank sum test was
used to assess the association between proteins and gender.
All p values were calculated with two-tailed significance
levels. All statistical analyses were performed using SAS
(version 9.1; SAS Institute; Cary, NC).
RESULTS
Patient Characteristics
Only gender and age were available for the patients
contributing specimens to the studied TMA. Nineteen (19%)
were women and 81 (81%) were men. The median age for all
patients was 54 years (range, 33–84).
Biomarker Expression Levels by AQUA and IHC
We used confocal microscopy to first determine the
dominant cellular compartment of expression for each
marker. As shown in Figure 1, RRM1, ERCC1, and Topo2
were predominantly nuclear in location, whereas TS was
predominantly cytoplasmic. All scores were measured using
the same scale.
AQUA
Most of the triplicate AQUA scores from each sample
were very close in value, suggesting little expression heter-
ogeneity for these proteins in SCLC (data not shown). Table
1 summarizes the key descriptive parameters for the average
AQUA scores of each of the biomarkers in the TMA. Nu-
merically, the scores followed the following order: ERCC1
TS  RRM1  Topo2 . The scores for Topo2 and RRM1
had a wide range. Conversely, the scores for ERCC1 and TS
had a narrow range and low values.
IHC
The descriptive parameters for the average H scores for
TS, GARFT, and FPGS are shown in Table 1. As with the
AQUA scores, both TS H scores tended to be low with
narrow ranges, whereas the scores for GARFT and FPGS
were higher and with wider ranges.
Associations Among Biomarker Expression
Levels, Age, and Gender
H scores for TS(106) and TS (4H4) were very strongly
correlated (r  0.82). More modest correlations were seen
between all other pairs of these two measures and TS AQUA
and GARFT H-scores (0.22  r  0.29). ERCC1 was
modestly correlated with all TS (AQUA and IHC) assess-
ments (0.27  r  0.34) and RRM1 (r  0.20), as shown in
Table 2. Topo2 levels were strongly and significantly cor-
related only with RRM1 (r  0.56, p  0.0001). Further-
more, the individual distribution of RRM1 and Topo2
AQUA scores (n  100) showed values more than both
median scores in 35 patients (35%) and less than both median
scores in 35 patients; in 15 patients, scores are only more than
one of each (i.e. among the 50 patients with high RRM1
values, 30% have low Topo2 levels and vice versa).
We used a two-dimensional spatial representation (Fig-
ure 2) to further examine the correlations between proteins.
The distance between the protein locations represents the
strength of the correlation (large distance represents low or
negative correlation). Two correlative groups are shown (Fig-
ure 2, left and right). ERCC1 (Figure 2, middle) played a
more central role but with slightly stronger correlations with
the TS biomarkers.
We found no significant correlations between expres-
sion levels for any of these biomarkers and the patients’ age
or gender.
DISCUSSION
Cancer develops as a result of gradual accumulation of
genetic alterations that can affect normal cellular processes
and function. The role that these “modified” gene products
play, when involved in the actions of cytotoxic agents, can be
used to tailor therapeutic choices; i.e. observed patterns of
sensitivity or resistance could be used to customize treat-
ments. A “customized” strategy has several advantages: (1)
patients are more likely to be treated with agents that they
will respond to, (2) patients can be spared the toxicity of
agents that they are resistant to, and (3) effective treatment
can be delivered early in the course of the disease.
Customized therapy has been previously investigated in
SCLC using in vitro drug sensitivity testing.41,42 In two trials,
SCLC cell suspensions were incubated with various concen-
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H69 cells
DAPI RRM1 Cytokeratin Merged
DAPI ERCC1 Cytokeratin Merged
DAPI MergedCytokeratinTopo IIa
DAPI MergedCytokeratinTS
FIGURE 1. Confocal microscopy images of the four biomarkers in the H69 small cell lung cancer cell line. DAPI, 4,6-dia-
midino-2-phenylindole; RRM1, ribonucleotide reductase 1; ERCC1, excision repair cross complementing group 1; TS, thymidy-
late synthase; Topo2, topoisomerase 2.
TABLE 1. Protein Expression Levels by AQUA and IHC in 100 Patients With SCLC
AQUA Score
AQUA (v 1.6) N Mean SD of Mean Median Minimum Maximum
RRM1, nuclear 100 568.5 168.4 550.7 143.4 1311.6
ERCC1, nuclear 100 19.9 6.5 18.1 11.3 48.1
Topo2, nuclear 100 652.9 226.2 634.7 246.2 1481.8
TS (antibody 106), cytoplasm 87 45.1 27.5 36.6 12.0 166.8
H Score
IHC N Mean SD of Mean Median Minimum Maximum
TS (antibody 106), cytoplasm 90 26.2 36.9 5.2 0.0 148.7
TS (antibody 4H4), cytoplasm 96 68.4 59.3 59.3 0.0 231.7
GARFT, nuclear 94 219.3 55.8 235.0 15.7 300.0
FPGS, cytoplasm 95 248.7 33.0 253.0 163.3 300.0
AQUA, automated quantitative analysis; IHC, immunohistochemistry; TS, thymidylate synthase; RRM1, ribonucleotide reductase 1;
ERCC1, excision repair cross-complementing group 1; Topo2, topoisomerase 2; GARFT, 5-phosphoribosyl-glycinamide formyl-
transferase; FPGS, folyl-polyglutamate synthase; SD, standard deviation.
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trations of individual cytotoxic drugs (cisplatin, etoposide,
adriamycin, cyclophosphamide, vincristine, methotrexate,
and carmustine). The dye exclusion assay43 was used for all
drug sensitivity tests to rank these seven drugs and to select
the in vitro best regimen. Although in both studies treatment
with individualized chemotherapy was feasible and associ-
ated with numerically favorable outcomes (compared with
nonrandomized controls), the studies were small, and the in
vitro best regimen selection proved labor intensive and time
consuming.44
These trials highlight the biggest obstacles that cus-
tomization therapy for SCLC currently faces: (1) lack of
defined predictive biomarkers and (2) lack of reliable and
reproducible technology to timely quantification. Multiple
preclinical and clinical studies have confirmed the role of
ERCC1, RRM1, Topo2, and TS as predictive biomarkers
for their respective cytotoxic agents,21–32 thus providing a
solution to the first obstacle. Solutions to the second obstacle
have proved to be more elusive.
For example, real-time polymerase chain reaction (RT-
PCR) analysis on FFPE tissue has been questioned due to
cross-linking and degradation of mRNA by formalin fixa-
tion.45 Furthermore, mRNA expression may not accurately
reflect protein expression and/or function. IHC provides in-
formation on protein expression and localization; thus, it is
the standard protein in situ assay. However, IHC scoring is
FIGURE 2. Multidimensional scaling plot of IHC
and AQUA scores.
TABLE 2. Correlations Among Biomarkers in 100 Patients With SCLC
ERCC1 AQUA
Nuclear
Topo2 AQUA
Nuclear
TS (106) AQUA
Cytoplasm
TS (106) IHC
Cytoplasm
TS (4H4) IHC
Cytoplasm
GARFT IHC
Nuclear
FPGS IHC
Cytoplasm
RRM1, AQUA nuclear r  0.20 r  0.56 r  0.12 r  0.02 r  0.06 r  0.01 r  0.21
p  0.05 p  0.0001 p  0.25 p  0.87 p  0.58 p  0.91 p  0.04
n  100 n  100 n  87 n  90 n  96 n  94 n  95
ERCC1, AQUA nuclear NA r  0.16 r  0.34 r  0.27 r  0.27 r  0.16 r  0.10
p  0.10 P  0.001 p  0.01 p  0.008 p  0.12 p  0.35
n  100 n  87 N  90 n  96 n  94 n  95
Topo2, AQUA nuclear NA r  0.08 r  0.04 r  0.11 r  0.15 r  0.20
p  0.45 p  0.71 p  0.27 p  0.14 p  0.05
n  87 n  90 n  96 n  94 n  95
TS (106), AQUA cytoplasm NA r  0.25 r  0.29 r  0.22 r  0.00
p  0.03 p  0.009 p  0.05 p  0.97
n  78 n  83 n  82 n  82
TS (106), IHC cytoplasm NA r  0.82 r  0.23 r  0.21
p  0.0001 p  0.03 p  0.05
n  90 n  90 n  89
TS (4H4), IHC cytoplasm NA r  0.28 r  0.16
p  0.007 p  0.12
n  94 n  95
GARFT, IHC nuclear NA r  0.02
p  0.89
n  93
r, Spearman correlation coefficient; n, number of observations; AQUA, automated quantitative analysis; IHC, immunohistochemistry; TS, thymidylate synthase; RRM1,
ribonucleotide reductase 1; ERCC1, excision repair cross-complementing group 1; Topo2, topoisomerase 2; GARFT, 5-phosphoribosyl-glycinamide formyl-transferase; FPGS,
folyl-polyglutamate synthase.
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semiquantitative, subjective, and highly dependent on poorly
controlled variables.46 TMAs reduce the variables in IHC
scoring and provide a high-throughput method to analyze
potential biomarkers on multiple samples but are limited by
the pathologist’s ability to reproducibly score on a continuous
scale, discriminate between subtle low-level staining differ-
ences, and accurately score expression within subcellular
components. In addition, TMAs cannot be used for real-time
patient specimen assessments.
AQUA is an immunofluorescence-based technique that
allows for rapid, automated, and quantitative analysis of
proteins,35 thus reducing the human variability occurring with
IHC scoring. AQUA automatically measures protein expres-
sion in subcellular compartments (i.e. nuclear versus cyto-
plasmic), providing a continuous score in an accurate, reli-
able, and reproducible way. Reported results in NSCLC37,47
not only confirm ERCC1, RRM1, and TS as important
biomarkers but also support AQUA as a valid methodology
for use.
The future use of biomarkers to customize chemother-
apy in patients with SCLC will first require a description of
the biomarker expression levels to identify the cut-off points
needed for dichotomization. Second, the biomarkers’ predic-
tive powers will need to be validated. In this report, we have
characterized the expression levels of four different proteins
in SCLC (Table 1) using AQUA. Furthermore, with the help
of confocal microscopy, we have also identified the appro-
priate subcellular compartment where each of these proteins
should be measured (nucleus for RRM1, ERCC1, and
Topo2 and cytoplasm for TS; Figure 1).
Not surprisingly, the AQUA scores for ERCC1 in our
investigation were universally and homogeneously low and
had a narrow distribution range (Table 1). This suggests a
uniform level of sensitivity to cisplatin, in accordance with
the well-known natural history of SCLC (typically sensitive
to cisplatin and radiation), and thus, renders the ERCC1-
cisplatin biomarker drug combination of low interest for
SCLC chemotherapy customization.
Although numerically higher than ERCC1 scores, TS
AQUA scores appear similarly low and narrow in range.
However, unlike cisplatin, pemetrexed has shown substan-
dard antitumor activity in recent SCLC trials.13 This is likely
related to the differential TS expression observed in different
lung cancer histologies. In NSCLC, TS expression (AQUA or
RT-PCR) is lower in adenocarcinomas than in squamous cell
carcinomas,47 correlating with the inferior antitumor activity
recently described for pemetrexed in the latter.48 Further-
more, SCLC TS mRNA expression seems to be even higher
than that of any NSCLC histology,49 thus, putatively explain-
ing the resistance to pemetrexed. Contrary to this observation
however, our SCLC TS AQUA scores appeared numerically
lower than those of both NSCLC histologies,47 but a direct
comparison is unfortunately precluded by the different tech-
nology versions used (different ranges, accuracy, and vari-
ability).
In contrast, the distributions observed for the Topo2
and RRM1 AQUA scores had much wider ranges (Table 1),
making them amenable to separation by a meaningful cut-off
point. Additionally, an analysis of the individual distribution
of Topo2 and RRM1 AQUA scores indicated that, in 30%
of patients, these scores localized at opposite sides of their
respective medians, suggesting the existence of “different
populations” identifiable by their Topo2 and RRM1 AQUA
scores, raising our enthusiasm for a possible chemotherapy
customization using Topo2 and RRM1 to select etoposide
and gemcitabine containing platinum regimens, respectively.
Of course, unlike pemetrexed, the known activity of etopo-
side and gemcitabine regimens in SCLC strengthens the
potential usefulness of these biomarkers as chemosensitivity
predictors.
The predictive and prognostic values of some of these
enzymes in SCLC have been recently reported.50 With the use
of mRNA extracted from microdissected sections of FFPE
biopsies from 103 LS- and patients with ES-SCLC, ERCC1,
RRM1, and Topo2 were quantified by RT-PCR. In limited
stage-SCLC, only Topo2 mRNA predicted for better re-
sponse (especially a complete response), and ERCC1 mRNA
was the only independent prognostic factor for survival. No
prognostic or predictive role was detected for any of these
genes in ES-SCLC. Given the small numbers and the limita-
tions inherent to the use of mRNA, reevaluation of these data,
using AQUA, is justified.
The ultimate goal is the design of a prospective clinical
trial in SCLC, where the predictive powers of these biomar-
ker expression levels are used to select the “most effective”
cytotoxic agents for an “individualized” combination. On the
basis of our present results, we hypothesize that selecting
etoposide and gemcitabine as part of a platinum-doublet
combination, based on Topo2 and RRM1 protein expres-
sion, is feasible and may improve the response and survival
rates of patients with SCLC. A clinical trial to test this
hypothesis is in development.
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